Cardiovascular
A disastrous Phase II miss for the pulmonary arterial hypertension candidate AV-101 leaves Aerovate drifting. Could Gossamer stand to benefit?
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results
CEO Bill Anderson would not be drawn on whether the drug, currently approved for chronic kidney disease associated with type 2 diabetes, will hit a previous forecast of €3bn peak sales, but expansion into heart failure may make that figure look conservative.
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.
Merck & Co. won European Commission approval for Winrevair on top of other medicines for pulmonary arterial hypertension and expects an initial EU launch in Germany.
Discontinuation of the AML study created concern about potential readthrough to a pivotal MDS trial, but the company and analysts pointed out differences in the diseases.
Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.
Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis.
Full data on heart disease products from Alnylam, Bayer and others will take center stage at the cardiology meeting later this month.
In this week's podcast edition of Five Must-Know Things: Pfizer bullish on its oral glp-1; BMS’s rising confidence about Medicare pricing of Eliquis; more long term data for Leqembi; NewAmsterdam’s CETP inhibitor shows promise; and a look at Mankind’s Bharat Serums buy.
Lilly is the first to demonstrate a benefit on heart failure outcomes with an incretin, even though rival Novo Nordisk already filed heart failure data for Wegovy with the US FDA.
Strides expects a licensing of Bhami’s formulation technology that enables subcutaneous delivery of biologics to boost associate company OneSource’s CDMO business. Meanwhile, its former CFO has been appointed MD and group CEO amid a US portfolio re-balance
The first Phase III trial testing the oral CETP inhibitor obicetrapib for the treatment of high cholesterol read out positively, years after some other drugs in the class failed.
The UK major has raised its full-year sales and earnings forecast on strong demand in the second quarter for its cancer, rare disease and cardiovascular medicines.
With sales of its big sellers Jardiance and Ofev to start shrinking in the next few years, the German group is teeing up a suite of new drugs.
The company’s series B venture capital will fund Phase IIb trials of PDE9 inhibitor CRD-750 in heart failure and a Phase IIa study of CaMKII inhibitor CRD-4730 in a rare arrhythmic disease.
Arrowhead’s in-house, late-stage cardiovascular disease programs will center on triglyceride-lowering plozasiran while it seeks a partner to fund Phase III for cholesterol-reducing zodasiran.
The company presented data showing it is possible to safely and effectively re-dose its ATTR amyloidosis CRISPR/Cas9-based therapy.